Table 1.
Highly cited papers (>100 citations) from 2012 and 2013 in infectious diseases
| 2012/2013 | N Engl J Med | Lancet | JAMA | JID | CID | CMI | Total | ISI | |
|---|---|---|---|---|---|---|---|---|---|
| Number articles/reviews | 709 | 1600 | 1230 | 164 | 955 | 556 | 5214 | >100.00 | |
| H factor | 141 | 114 | 481 | 44 | 48 | 31 | |||
| Number of citations in 2015 per papers (Infect Dis/Med Microbiol) | 97 | 30 | 25 | 40 | 17 | 11 | |||
| Articles cited >100 times | 234 (33%) | 133 (8%) | 51 (4%) | 12 (7%) | 6 (0,6%) | 4 (0,7%) | 200 (0.2%) | ||
| Malaria | 0 | 2 | 0 | 0 | 0 | 0 | 2 (3%) | 30% | 5 (2.5%) |
| Tuberculosis | 3 | 0 | 0 | 2 | 1 | 0 | 6 (9%) | 13 (6.5%) | |
| HIV | 5 | 4 | 1 | 2 | 0 | 0 | 11 (17%) | 35 (17.5%) | |
| Hepatitis | 4 | 1 | 1 | 0 | 0 | 0 | 5 | 8% | 26 (13%) |
| H7 N9 | 3 | 3 | 0 | 0 | 0 | 0 | 8 | 13% | 9 (4.5%) |
| MERS coronavirus | 1 | 0 | 0 | 1 | 0 | 0 | |||
| Resistance to antibiotics + Neo antibiotics | 0 | 1 | 0 | 3 | 4 | 2 | 10 | 16% | 26 (13%) |
| Vaccines | 3 | 0 | 0 | 2 | 0 | 0 | 5 | 8% | 14 (7%) |
| Mycology | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3% | 11 (5.5%) |
| Microbiota | 2 | 0 | 1 | 0 | 0 | 1 | 3 | 5% | 70 (35%) |
| Total >100 Infect. Dis.; p < 0.001 | 27 (4%) | 15 (1%) | 4 (0.4%) | 12 (7%) | 6 (0.6%) | 4(0.7%) | 64 | 200 (1.2%) |
H7N9, avian influenza virus H7N9; HIV, human immunodeficiency virus; MERS, Middle East respiratory syndrome; N Engl J Med, The New England Journal of Medicine; JAMA, Journal of the American Medical Association; JID, The Journal of Infectious Diseases; CID, Clinical Infectious Disease; CMI, Clinical Microbiology and Infections.